LY01015

Shandong Boan Biotechnology Co., Ltd · Phase 3 active Small molecule

LY01015 is a small molecule inhibitor that targets a specific molecular pathway involved in disease pathogenesis.

At a glance

Generic name	LY01015
Sponsor	Shandong Boan Biotechnology Co., Ltd
Modality	Small molecule
Phase	Phase 3

Mechanism of action

LY01015 is an investigational compound in phase 3 development by Shandong Boan Biotechnology. Limited public information is available regarding its precise molecular mechanism and target. The drug is being evaluated for therapeutic potential, but detailed mechanistic data has not been widely disclosed in accessible literature.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell Carcinoma (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

LY01015 CI brief — competitive landscape report
LY01015 updates RSS · CI watch RSS
Shandong Boan Biotechnology Co., Ltd portfolio CI